Daraxonrasib Pancreatic Cancer Drug 2026 is becoming one of the most important treatment updates for pancreatic cancer patients and families in the USA, UK, Singapore, Canada, Australia and Singapore. Daraxonrasib, also known as RMC-6236, is an investigational once-daily oral RAS-targeted therapy being studied for previously treated metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
For many patients, the biggest question is not only whether a new drug can slow cancer growth, but whether it can help them gain more meaningful time, better symptom control and a stronger path forward after standard chemotherapy. That is why Daraxonrasib Pancreatic Cancer Drug 2026 has become a highly searched topic among patients, caregivers and oncology specialists.
In 2026, daraxonrasib attracted attention after Phase 3 clinical trial results showed longer survival and longer progression-free survival compared with standard chemotherapy in previously treated metastatic pancreatic cancer patients. While it is not yet a guaranteed solution or a universally available treatment in every country, it may become an important new option for eligible patients after regulatory review.
What is daraxonrasib?
Daraxonrasib is an investigational oral RAS(ON) inhibitor. In simpler words, it is designed to block overactive RAS signaling, a cancer-driving pathway that is especially important in pancreatic cancer [1]. RAS mutations, including KRAS mutations, are found in a very high proportion of pancreatic ductal adenocarcinomas, which is one reason researchers have been trying for decades to target this pathway successfully [2].
Older cancer treatments such as chemotherapy attack rapidly dividing cells more broadly. Daraxonrasib is different because it is a targeted therapy. It aims at the molecular engine that helps many pancreatic cancer cells keep growing. This does not mean it works for every patient, and resistance can still develop, but it represents a more precise treatment direction than conventional second-line chemotherapy alone [3].
| Patient question | Current answer in 2026 |
|---|---|
| Drug name | Daraxonrasib |
| Trial name | RASolute 302 |
| Other name | RMC-6236 |
| Drug type | Oral RAS(ON) multi-selective inhibitor |
| Main studied use | Previously treated metastatic pancreatic ductal adenocarcinoma |
| How it is taken in the Phase 3 trial | Once-daily oral tablet |
| Approval status | Investigational; access depends on country, trial availability, and expanded access pathways |
| Why it matters | It showed longer survival, longer progression-free survival, and delayed worsening of pain and quality of life compared with chemotherapy |
Why the 2026 daraxonrasib results matter
The key study is RASolute 302, a global randomized Phase 3 trial in patients with previously treated metastatic PDAC. In the trial, 500 patients were assigned to either daraxonrasib or the investigator’s choice of standard chemotherapy [2]. The study compared survival, cancer progression, side effects, and quality-of-life outcomes.
The headline result is striking. In the overall study population, median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy [2]. In patients with RAS G12 mutations, median overall survival was 13.2 months with daraxonrasib compared with 6.6 months with chemotherapy [2]. This does not mean every patient lives exactly that long. Median survival means half of the patients lived longer than that number and half lived less. Still, for metastatic pancreatic cancer after prior treatment, this difference is clinically meaningful.
Progression-free survival also improved. In the overall population, median progression-free survival was 7.2 months with daraxonrasib compared with 3.6 months with chemotherapy [2]. In the RAS G12 group, median progression-free survival was 7.3 months compared with 3.5 months [2]. For patients, this may translate into more time before the cancer visibly worsens on scans or symptoms progress.
| RASolute 302 result | Daraxonrasib | Standard chemotherapy |
|---|---|---|
| Patients in trial | 248 | 252 |
| Median overall survival, overall population | 13.2 months | 6.7 months |
| Median overall survival, RAS G12 group | 13.2 months | 6.6 months |
| Median progression-free survival, overall population | 7.2 months | 3.6 months |
| Median progression-free survival, RAS G12 group | 7.3 months | 3.5 months |
| Grade 3 or higher treatment-related side effects | 43.6% | 57.5% |
| Treatment discontinuation due to treatment-related side effects | 1.2% | 11.2% |
Is daraxonrasib approved?
As of July 2026, daraxonrasib should still be discussed as an investigational medicine, not a universally available standard prescription. The U.S. FDA has allowed an expanded access treatment protocol for eligible patients with previously treated metastatic PDAC, which may help some U.S. patients receive daraxonrasib before full approval if they meet criteria and a licensed physician applies on their behalf [4].
In Europe, the European Medicines Agency began a phased review of daraxonrasib on July 7, 2026, to accelerate assessment because metastatic pancreatic cancer after prior treatment has limited options and a poor prognosis [5]. In the UK, a government response dated June 10, 2026 stated that daraxonrasib was not currently licensed in the United Kingdom and was not yet in NICE’s work programme at that time [6].
For patients in Singapore, Canada, and Australia, the safest message is to check local regulatory pathways and speak with an oncologist at a major cancer center. Patients may need to ask about clinical trials, compassionate access, overseas treatment planning, or future approval timelines. In Singapore, patients can check the Health Sciences Authority register; in Canada, the Health Canada Drug Product Database is the official source for authorized drugs; and in Australia, the Therapeutic Goods Administration and ARTG are the official routes for medicine registration checks [7][8][9].
Who might be eligible?
The main 2026 Phase 3 data apply to patients with metastatic pancreatic ductal adenocarcinoma whose disease has already been treated before [2]. Many reports describe this as a second-line setting, meaning after one prior line of therapy. Eligibility for daraxonrasib through a trial or expanded access program may depend on diagnosis, cancer stage, prior treatment, current health, organ function, blood tests, performance status, and whether the patient can safely take the medicine [4].
Patients should not delay standard treatment while waiting for daraxonrasib. Pancreatic cancer can move quickly, and every treatment decision should be made with an oncology team. A practical next step is to ask the oncologist: “Do I have metastatic PDAC, have I had the right biomarker testing, and am I eligible for daraxonrasib through a trial, expanded access program, or future approved pathway?” [10].
Does every patient need KRAS or RAS testing?
Biomarker testing remains important. Even though the RASolute 302 results showed benefit in the overall population, including patients with and without an identified tumor RAS mutation, experts still recommend genomic testing because pancreatic cancer can occasionally have other actionable alterations [10]. A patient without a common KRAS mutation may have a rare target that leads to a different treatment option or clinical trial.
For SEO and patient clarity, this is an important point: daraxonrasib is often described as a KRAS or RAS pancreatic cancer drug, but patients should not assume eligibility based only on a news headline. A tumor profile, treatment history, and physician review matter.
Side effects patients should know
Daraxonrasib is not side-effect free. In RASolute 302, grade 3 or higher treatment-related adverse events occurred in 43.6% of patients receiving daraxonrasib compared with 57.5% receiving chemotherapy [2]. The most discussed side effects included rash and stomatitis, which means mouth inflammation or mouth sores [2]. Some patients may also experience digestive symptoms, fatigue, or other treatment-related issues depending on their overall condition and other medicines.
The encouraging part is that fewer patients stopped daraxonrasib because of treatment-related side effects compared with chemotherapy in the trial [2]. That matters because staying on treatment can be important for disease control. Patients should still report rash, mouth sores, diarrhea, appetite changes, dehydration, fever, weakness, or pain early so the care team can intervene quickly.
How Ayurveda may help during pancreatic cancer care
Ayurveda can be positioned most responsibly as integrative support, not as a replacement for oncology treatment. In pancreatic cancer, the body often struggles with digestion, appetite, weight loss, fatigue, pain, anxiety, and treatment tolerance. A carefully supervised Ayurvedic plan may support the patient’s healing environment by focusing on digestion, nourishment, sleep, stress regulation, gentle movement, and strength preservation. This is where Ayurveda can feel genuinely valuable for patients: not by replacing daraxonrasib, chemotherapy, surgery, or radiation, but by helping the person remain steadier through the treatment journey [11].
A good integrative approach may include personalized diet guidance, digestion-supportive routines, gentle yoga or breathing practices, relaxation methods, and carefully selected herbal support only after oncology approval. Patients can explore Panaceayur’s pancreatic cancer Ayurveda support page here: https://panaceayur.com/disease-cure/oncology/pancreatic-cancer/. The wording should stay honest and patient-centered: Ayurveda may support recovery strength, inner balance, appetite, comfort, and treatment resilience, while modern oncology targets the tumor directly.
This safety line is important for trust and ranking in the USA, UK, Canada, Singapore, and Australia: patients should never stop prescribed cancer treatment or start herbs without telling their oncologist. The U.S. National Cancer Institute warns that no special diet, supplement, herb, or combination has been proven to slow cancer, remove it completely, or prevent it from returning, and some products may interfere with cancer treatment [11]. Cancer Research UK also notes that some Ayurvedic herbal medicines may interact with cancer drugs or radiotherapy, and some products may contain harmful substances [12]. The most convincing Ayurveda message is therefore not “instead of oncology,” but “alongside oncology, safely supervised, to help the body stay stronger.”
What should patients ask their oncologist?
Patients and families should ask whether the diagnosis is pancreatic ductal adenocarcinoma, whether the cancer is metastatic, which prior treatments have already been used, whether full biomarker testing has been done, and whether daraxonrasib access is possible through clinical trials, expanded access, or future approved routes. They should also ask how side effects such as rash, mouth sores, diarrhea, pain, and appetite loss will be managed.
Patients using Ayurveda, herbs, supplements, detox programs, or special diets should bring the full list to every oncology visit. This protects safety and helps the care team avoid interactions. A combined plan is strongest when the oncologist, dietitian, palliative care team, and qualified Ayurveda practitioner work together.
Final takeaway
Daraxonrasib is one of the most hopeful pancreatic cancer drug stories of 2026. It is a once-daily oral RAS-targeted therapy that significantly improved survival and delayed cancer progression in previously treated metastatic pancreatic cancer compared with standard chemotherapy [2]. It is not a simple promise, and it is not available to every patient in every country today. But it may become a major new treatment pathway if regulators approve it.
For patients, the smartest path is to act early: ask about biomarker testing, ask about daraxonrasib trials or access programs, continue evidence-based oncology care, and use Ayurveda only as a supervised supportive layer for strength, digestion, comfort, and resilience. The goal is not just more time, but better-supported time, with the body and mind cared for throughout the journey.
References
[1] Revolution Medicines. Daraxonrasib Phase 3 RASolute 302 topline results, April 13, 2026. Shows daraxonrasib improved overall survival and progression-free survival versus chemotherapy and states the drug was investigational.
https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit (Revolution Medicines)
[2] Revolution Medicines. ASCO Plenary and NEJM publication announcement, May 31, 2026. Gives detailed RASolute 302 results, including survival, PFS, safety, and quality-of-life findings.
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation (Revolution Medicines)
[3] Stanford Medicine. Five things to know about daraxonrasib, June 24, 2026. Explains how the drug works, why pancreatic cancer is difficult to treat, and why the drug is promising but not a final answer.
https://med.stanford.edu/news/insights/2026/06/pancreatic-cancer-drug-daraxonrasib-what-to-know.html (Stanford Medicine)
[4] U.S. FDA. FDA permits expanded access for investigational pancreatic cancer drug, May 1, 2026. Confirms FDA safe-to-proceed letter for expanded access protocol.
https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug (U.S. Food and Drug Administration)
[5] European Medicines Agency. EMA fast-tracks review of a medicine for metastatic pancreatic cancer, July 7, 2026. Confirms phased review of daraxonrasib by CHMP.
https://www.ema.europa.eu/en/news/ema-fast-tracks-review-medicine-metastatic-pancreatic-cancer (European Medicines Agency (EMA))
[6] UK Parliament. Daraxonrasib licensing answer, June 10, 2026. States daraxonrasib was not currently licensed in the UK and not in NICE’s work programme at that time.
https://questions-statements.parliament.uk/written-questions/detail/2026-06-01/HL517/ (UK Parliament)
[7] Singapore Health Sciences Authority. Listing of therapeutic product approvals. Official page for checking Singapore therapeutic product approvals and registration updates.
https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/tools-and-resources/listing-of-approvals-and-post-registration-actions/listing-of-approvals/ (Health Sciences Authority)
[8] Health Canada. Drug Product Database. Official database for drugs authorized for sale by Health Canada.
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (Canada)
[9] Therapeutic Goods Administration Australia. Searching the Australian Register of Therapeutic Goods. Official source for checking Australian medicine registrations.
https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg (Therapeutic Goods Administration (TGA))
[10] Pancreatic Cancer Action Network. Patient guidance on daraxonrasib, biomarker testing, expanded access, and not delaying treatment.
https://pancan.org/news/first-ras-inhibitor-extends-survival-in-previously-treated-metastatic-pancreatic-adenocarcinoma-what-you-need-to-know/ (Pancreatic Cancer Action Network)
[11] National Cancer Institute. Complementary and Alternative Medicine. Explains safety concerns, evidence limits, and the need to discuss supplements with doctors.
https://www.cancer.gov/about-cancer/treatment/cam (Cancer.gov)
[12] Cancer Research UK. Ayurvedic medicine and cancer. Explains safety issues, herb-drug interactions, and why patients should not rely entirely on Ayurveda for cancer treatment.
https://www.cancerresearchuk.org/about-cancer/treatment/complementary-alternative-therapies/individual-therapies/ayurvedic-medicine (cancerresearchuk.org)
